Here are the 8-K filings from Attovia Therapeutics, Inc. (ATTO) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow ATTO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ATTO filings page.
Attovia Therapeutics, Inc. (ATTO) reported second quarter 2026 results and a corporate update, highlighted by preliminary clinical proof of concept for lead candidate ATTO-1310 in chronic pruritus and high-itch atopic dermatitis, showing rapid, deep itch relief and lesion control in a Phase 1b study.
The company plans two global Phase 2 trials of ATTO-1310 in chronic pruritus of unknown origin and high-itch atopic dermatitis, both targeted to start in the first half of 2027, and is advancing ATTO-2306 and ATTO-1091 toward Phase 1 initiation in the same timeframe. Early program ATTO-006 is being moved toward development candidate nomination by year-end 2026.
Attovia completed an upsized IPO with $332.4 million in gross proceeds and expects that existing cash, cash equivalents and marketable securities, including $305.4 million of IPO net proceeds, will fund operations into 2030. For the quarter ended June 30, 2026, collaboration revenue was $0.5 million, research and development expenses were $18.9 million, and net loss was $20.7 million. Cash, cash equivalents and marketable securities were $115.1 million as of June 30, 2026, prior to the August IPO.
Attovia Therapeutics, Inc. implemented an Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws on August 6, 2026, in connection with the closing of its initial public offering of common stock, par value $0.0001 per share. The board of directors and stockholders had previously approved these revised governing documents to become effective immediately prior to the offering’s closing, as described in the company’s final prospectus dated August 4, 2026. The company’s common stock trades under the symbol ATTO on the Nasdaq Global Market.